FDA 批准替莫唑胺应用于多形性胶质瘤

Temodar(R) Approved by FDA for Newly Diagnosed Glioblastoma Patients (3/24/2005)
On March 15, 2005 the US Food and Drug Administration (FDA) approved oral Temodar® (temozolomide) in combination with radiation therapy for the initial treatment of patients with glioblastoma multiforme (GBM). FDA approval was for concomitant treatment with oral Temodar® and radiation therapy followed by maintenance therapy with Temodar®.
包括联合、同期放疗，以及维持治疗。